GCGR

General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares

$10.07

+$0.00 (+0.00%)Today

Key Statistics

Market cap509.15M

Price-Earnings ratio—

Dividend yield—

Average volume29.34K

High today$10.07

Low today$10.05

Open price$10.05

Volume370.14K

52 Week high$10.22

52 Week low$9.96

Company Profile

Description

General Catalyst Global Resilience Merger Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2026 and is based in Cambridge, Massachusetts.

Sector

Financial Services

Industry

Shell Companies

CEO

Mr. Paul S. Kwan

Website

globalresiliencemergercorp.com

Company Profile

Description

Sector

Financial Services

Industry

Shell Companies

CEO

Mr. Paul S. Kwan

Website

globalresiliencemergercorp.com

GCGR

Key Statistics

Company Profile

Company Profile

Recent News

Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

General Catalyst Global Resilience Merger Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing on June 22, 2026

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726

Recent News

Company Profile

Recent News

Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

General Catalyst Global Resilience Merger Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing on June 22, 2026

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726